Journal
DRUG DISCOVERY TODAY
Volume 22, Issue 3, Pages 546-554Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.10.003
Keywords
-
Categories
Funding
- Bill & Melinda Gates Foundation [OPP1024021]
- Wellcome Trust
- Biotechnology and Biological Sciences Research Council [1103577] Funding Source: researchfish
- Medical Research Council [MR/M026302/1, MR/N501864/1] Funding Source: researchfish
- MRC [MR/N501864/1, MR/M026302/1] Funding Source: UKRI
Ask authors/readers for more resources
Fragment-based drug discovery is now widely used in academia and industry to obtain small molecule inhibitors for a given target and is established for many fields of research including antimicrobials and oncology. Many molecules derived from fragment-based approaches are already in clinical trials and two - vemurafenib and venetoclax - are on the market, but the approach has been used sparsely in the tuberculosis field. Here, we describe the progress of our group and others, and examine the most recent successes and challenges in developing compounds with antimycobacterial activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available